Pre-operative IL13-PE38QQR [cintredekin besudotox] infusion in patients with recurrent or progressive supratentorial malignant glioma: a phase I/II study.
Phase of Trial: Phase I/II
Latest Information Update: 30 Apr 2014
At a glance
- Drugs Cintredekin besudotox (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 31 Aug 2018 Biomarkers information updated
- 03 Jun 2011 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
- 03 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.